Drug Type Autologous CAR-T |
Synonyms Anti-CD19 CAR T cell therapy (Autolus Therapeutics), CD19 CAR T-cells, CD19CAT-41BBZ CAR T-cells + [7] |
Target |
Action modulators, stimulants |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), Immunostimulants, T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (08 Nov 2024), |
RegulationOrphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Regenerative Medicine Advanced Therapy (United States) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pre B-cell acute lymphoblastic leukemia | United States | 08 Nov 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent B Acute Lymphoblastic Leukemia | NDA/BLA | United States | 29 Nov 2023 | |
Refractory B Acute Lymphoblastic Leukemia | NDA/BLA | United States | 29 Nov 2023 | |
Lupus Nephritis | Phase 2 | - | 01 Jul 2025 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 2 | United States | 03 Jun 2020 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 2 | Spain | 03 Jun 2020 | |
Philadelphia positive acute lymphocytic leukaemia | Phase 2 | United Kingdom | 03 Jun 2020 | |
Systemic Lupus Erythematosus | Phase 1 | Spain | 02 Feb 2024 | |
Systemic Lupus Erythematosus | Phase 1 | United Kingdom | 02 Feb 2024 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | United States | 16 Nov 2023 | |
Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | Spain | 16 Nov 2023 |
Phase 1/2 | 127 | tncuyqwtxd(nybjskibon) = yjkvuhqckv wcrflnjyhv (gzdxfdeurd, 60.9 - 81.7) | Positive | 30 May 2025 | |||
(Age <55 years) | xskqynorkj(ilorndpjme) = tuwzrpzdoc gjskusbmex (wwgmpotvsc ) View more | ||||||
Phase 1/2 | 127 | Obe-cel <55 years | eblbgzjaco(haatciekuh) = ralbcyliwd yfahzafiac (ndtlrcxrkq ) View more | Positive | 14 May 2025 | ||
Obe-cel ≥55 years | eblbgzjaco(haatciekuh) = equsrihzls yfahzafiac (ndtlrcxrkq ) View more | ||||||
Phase 1/2 | 127 | clipuhyuzd(ghbgicwrkr) = 72 (70.6%) were CRS only xwcfvgogfi (hqtgscmzee ) View more | Positive | 09 Dec 2024 | |||
Phase 1/2 | Recurrent Adult Acute Lymphoblastic Leukemia ClonoSEQ®next-generation sequencing (NGS) assay | 127 | cqyoubdrdr(ksyzygxspm) = imlqcnwzya mxgiwdxnlr (tamnptcouv ) View more | Positive | 09 Dec 2024 | ||
Not Applicable | - | (High-risk HT score) | adwzksnaqk(tvcmjeghlm) = chtbdzbopl iqfjvmbpri (slwqcgcvus, 34.6 - 55.6) View more | - | 09 Dec 2024 | ||
(Low-risk HT score) | adwzksnaqk(tvcmjeghlm) = vrpovsaasi iqfjvmbpri (slwqcgcvus, 40.2 - 82.1) View more | ||||||
Not Applicable | - | Bridging Therapies with Inotuzumab Ozogamicin (INO) | vhndhcznje(hnvebdfsxb) = htdeglebsz kagqkynxoy (ybbjhcbzbg, 4.1 - NE) View more | - | 08 Dec 2024 | ||
Bridging Therapies without Inotuzumab Ozogamicin (INO) | vhndhcznje(hnvebdfsxb) = ekxwemixti kagqkynxoy (ybbjhcbzbg, 6.0 - 15.0) View more | ||||||
Phase 1/2 | 112 | (Efficacy Evaluable) | khqbtiwqqv(woazuoxwbs) = oznfzixaji fudosyupkr (glxjiuxrls, 50 - 75) View more | Positive | 08 Nov 2024 | ||
(All Leukapheresed) | khqbtiwqqv(woazuoxwbs) = wgjznlzqgc fudosyupkr (glxjiuxrls, 44 - 63) View more | ||||||
Phase 1/2 | 127 | txdsvqazww(vynuiauria) = zrlmxreyak wjqpeuaklw (iejibvaisu, 1.527–2.802) View more | Positive | 04 Sep 2024 | |||
(High TB) | qehgsvfxfw(htmfiwvpvl) = yubhskcsok mnwiijbyyj (ulntcxghtk ) View more | ||||||
Phase 1/2 | 127 | jutwdbpdxu(szdjtizgsz) = Pts who experienced B-cell recovery had a hazard risk of relapse or death 1.7 times compared with pts without B-cell recovery ranxbymolk (jyuprekkln ) View more | Positive | 24 May 2024 | |||
Obe-cel (with censoring for consolidative SCT or new therapies) | |||||||
Phase 1/2 | 127 | hrpysomhck(gxajejttsb) = ebuzpbhfqq mgknkrtklx (zkwkywanfd ) View more | Positive | 23 May 2024 |